More MS news articles for June 2002

Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients

http://www.neurology.org/cgi/content/abstract/58/12/1786

Neurology 2002;58:1786-1790
A.-M. Vallittu, MD, M. Halminen, MD, PhD, J. Peltoniemi, BMed, J. Ilonen, MD, PhD, I. Julkunen, MD, PhD, A. Salmi, MD, PhD, J.-P. Erälinna, MD, PhD and the Finnish Beta-Interferon Study Group
From the Departments of Virology (Drs. Vallittu, Halminen, Peltoniemi, Ilonen, Salmi, and Erälinna) and Neurology (Dr. Erälinna), Turku Immunology Centre and University of Turku, and Turku Graduate School of Biomedical Sciences (Drs. Halminen and Peltoniemi); and National Public Health Institute (Dr. Julkunen), Helsinki, Finland.

Background:

Neutralizing antibodies (NAb) during interferon-beta (IFNß) treatment of MS are associated with reduced clinical and MR efficacy. NAb inhibit the IFN- inducible MxA gene expression and neutralize the capability of IFNß to inhibit virus growth in vitro. Presently, there is no clear concept of the biologic importance of IFNß antibodies; most of the tests applied for the detection of NAb in previous publications are not widely available, and the results are not fully comparable.

Methods:

A 1-year prospective study of the development of binding antibodies (BAb) and NAb and their relationship to IFN-inducible MxA protein levels in peripheral blood leukocytes in 20 IFNß-1a-treated patients with relapsing–remitting MS was conducted.

Results:

In seven of nine NAb-positive patients, IFNß-1a was unable to induce MxA protein. BAb were detected in 11 patients, and they preceded or paralleled the development of NAb in all the patients. The titer of NAb correlated positively with BAb titer and negatively with MxA expression level. There was also a weaker but clear correlation between BAb titers and MxA levels.

Conclusions:

NAb, in most but not all cases, inhibited the in vivo function of IFNß. Analysis of MxA protein in lymphocytes together with analysis of NAb is a promising marker for evaluating the biologic effects of IFNß treatment in MS patients.

© 2002 American Academy of Neurology